Back to Journals » Breast Cancer: Targets and Therapy

Breast Cancer: Targets and Therapy

ISSN: 1179-1314


Journal Articles:

- 483 records -

Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer

Ubowski MM, VanSice R, Marriott M, Yacobucci MJ, Chablani L

Breast Cancer: Targets and Therapy 2024, 16:149-162

Published Date: 28 March 2024

HER2 Low Expression in Primary Male Breast Cancer

Nobbe K, Erices-Leclercq M, Foerster F, Förster R, Baldus SE, Rudlowski C, Schröder L, Lubig S

Breast Cancer: Targets and Therapy 2024, 16:141-148

Published Date: 28 March 2024

ZNF217 Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer

Rangel N, Sánchez IL, Valbuena DS, Rondón-Lagos M

Breast Cancer: Targets and Therapy 2024, 16:127-139

Published Date: 15 March 2024

The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients

Ma Q, Liu YB, She T, Liu XL

Breast Cancer: Targets and Therapy 2024, 16:117-126

Published Date: 8 March 2024

Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting

Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, Drizon A, Chodick G, Siegelmann-Danieli N

Breast Cancer: Targets and Therapy 2024, 16:105-116

Published Date: 6 March 2024

GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer

Zhou Y, Xue W, Meng X, Bhandari A, Zeng H, KC R, Hirachan S, Xia E

Breast Cancer: Targets and Therapy 2024, 16:71-89

Published Date: 5 March 2024

Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads

Monteiro MR, Nunes NCC, Junior AADS, Fêde ABDS, Bretas GDO, Souza CDP, Mano M, da Silva JL

Breast Cancer: Targets and Therapy 2024, 16:51-70

Published Date: 28 February 2024

Does Nipple-Ward Positive Margin Contribute to a Higher Rate of Re-Excision Procedures After a Lumpectomy with Pathology-Confirmed Positive Margins? A Retrospective Study

Bhimani F, Lin S, McEvoy M, Cavalli A, Obaid L, Chen Y, Gupta A, Pastoriza J, Shihabi A, Feldman S

Breast Cancer: Targets and Therapy 2024, 16:41-50

Published Date: 21 February 2024

Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse Disease-Free Survival in Patients with Breast Cancer

Chen CC, Tang WH, Wu CC, Lee TL, Tsai IT, Hsuan CF, Wang CP, Chung FM, Lee YJ, Yu TH, Wei CT

Breast Cancer: Targets and Therapy 2024, 16:23-39

Published Date: 16 January 2024

Thyroid Hormone Changes Correlate to Combined Breast Cancer with Primary Thyroid Cancer

Jin J, Li J, Liu Y, Shi Q, Zhang B, Ji Y, Hu P

Breast Cancer: Targets and Therapy 2024, 16:15-22

Published Date: 9 January 2024

The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors

Ekemen S, Bilir E, Soultan HEA, Zafar S, Demir F, Tabandeh B, Toprak S, Yapicier O, Coban C

Breast Cancer: Targets and Therapy 2024, 16:1-13

Published Date: 3 January 2024

CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1

Zhu X, Yu J, Ai F, Wang Y, Lv W, Yu G, Cao X, Lin J

Breast Cancer: Targets and Therapy 2023, 15:967-984

Published Date: 28 December 2023

Immunotherapy: Constructive Approach for Breast Cancer Treatment

Anayyat U, Ahad F, Muluh TA, Zaidi SAA, Usmani F, Yang H, Li M, Hassan HA, Wang X

Breast Cancer: Targets and Therapy 2023, 15:925-951

Published Date: 15 December 2023

Breast Cancer Awareness Among Women in Saudi Arabia: A Systematic Review

AlRajhi B, Aljadani FF, Almarwan SR, Alzahrani AA, Sindi MHM, Kano A, Alzahrani RS, Baaqeel R

Breast Cancer: Targets and Therapy 2023, 15:913-924

Published Date: 14 December 2023

Accuracy Rate of Methylene Blue Injection in Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Patients: A Prospective Observational Study

Aziz HK, Azhar Y, Widarda IR, Abdurahman M, Erdiansyah Z, Nugraha P, Lukman K

Breast Cancer: Targets and Therapy 2023, 15:891-897

Published Date: 7 December 2023

Evaluation of Cytotoxicity of the Methanolic Extract of Red Sea Marine Sponge Xestospongia Testudinaria and Its Related Compounds Against MCF-7 Human Breast Cancer Cells

Alkhilaiwi FA, Fadil SA, Aljoud FA, Yonbawi AR, Ashi A, Hareeri RH, Bakhashab S, Alamri AM, Albikairi AY, Shaala LA, El-Gamal AA, Youssef DT

Breast Cancer: Targets and Therapy 2023, 15:879-890

Published Date: 7 December 2023

Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases

Huang J, Zhu W, Duan Q, Zhu C, Shi X, Zhao H, Cai P, Li D

Breast Cancer: Targets and Therapy 2023, 15:841-853

Published Date: 17 November 2023

ABCB1 Regulates Immune Genes in Breast Cancer

Chen HK, Chen YL, Wang CY, Chung WP, Fang JH, Lai MD, Hsu HP

Breast Cancer: Targets and Therapy 2023, 15:801-811

Published Date: 13 November 2023

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T

Breast Cancer: Targets and Therapy 2023, 15:785-799

Published Date: 6 November 2023

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management

Gorenšek R, Kresnik M, Takač I, Rojko T, Sobočan M

Breast Cancer: Targets and Therapy 2023, 15:773-783

Published Date: 2 November 2023

A Review on the Management of Peripheral Neuropathic Pain Following Breast Cancer

Avila F, Torres-Guzman R, Maita K, Garcia JP, De Sario GD, Borna S, Ho OA, Forte AJ

Breast Cancer: Targets and Therapy 2023, 15:761-772

Published Date: 30 October 2023

Traditional Chinese Medicine for Breast Cancer: A Review

Feng RQ, Li DH, Liu XK, Zhao XH, Wen QE, Yang Y

Breast Cancer: Targets and Therapy 2023, 15:747-759

Published Date: 27 October 2023

Hsa_circ_0007823 Overexpression Suppresses the Progression of Triple-Negative Breast Cancer via Regulating miR-182-5p-FOXO1 Axis

Yu J, Wang H, Shen W, Zhou Y, Cui J, Li H, Gao B

Breast Cancer: Targets and Therapy 2023, 15:695-708

Published Date: 18 October 2023

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification

Ünal Ç, Özmen T, İlgün AS, Ordu Ç, Özkurt E, Ak N, Alço G, Erdoğan İyigün Z, Kurt S, Duymaz T, Öztürk MA, Elbüken Çelebi F, Yararbaş K, Soybir G, Aktepe F, Özmen V

Breast Cancer: Targets and Therapy 2023, 15:659-669

Published Date: 1 September 2023

Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer

Tong L, Yu X, Wang S, Chen L, Wu Y

Breast Cancer: Targets and Therapy 2023, 15:647-658

Published Date: 24 August 2023

Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan

Haque R, Chen LH, Oestreicher N, Lalla D, Chlebowski RT

Breast Cancer: Targets and Therapy 2023, 15:637-645

Published Date: 16 August 2023

ABVS-Based Radiomics for Early Predicting the Efficacy of Neoadjuvant Chemotherapy in Patients with Breast Cancers

Jiang W, Deng X, Zhu T, Fang J, Li J

Breast Cancer: Targets and Therapy 2023, 15:625-636

Published Date: 15 August 2023

HER2-Low Breast Cancer: Current Landscape and Future Prospects

Shirman Y, Lubovsky S, Shai A

Breast Cancer: Targets and Therapy 2023, 15:605-616

Published Date: 14 August 2023

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

Bai Q, Lv H, Bao L, Yang Y, Zhang X, Chang H, Xue T, Ren M, Zhu X, Zhou X, Yang W

Breast Cancer: Targets and Therapy 2023, 15:563-575

Published Date: 3 August 2023

Early but Quality Diagnosis: On Breast Cancer and Its Risk Factors [Letter]

Zehra SS, Turabee Z, Rawalia MA

Breast Cancer: Targets and Therapy 2023, 15:549-550

Published Date: 1 August 2023

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib

Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H

Breast Cancer: Targets and Therapy 2023, 15:541-548

Published Date: 28 July 2023

“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”

Höller A, Nguyen-Sträuli BD, Frauchiger-Heuer H, Ring A

Breast Cancer: Targets and Therapy 2023, 15:525-540

Published Date: 28 July 2023

Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression

Purwanto I, Leo B, Hutajulu SH, Kurnianda J, Taroeno-Hariadi KW, Hardianti MS, Satiti AD, Dwianingsih EK, Heriyanto DS, Widodo I, Aryandono T

Breast Cancer: Targets and Therapy 2023, 15:515-524

Published Date: 27 July 2023

More articles